Canaccord Genuity Maintains Buy on Guardant Health, Raises Price Target to $125

Benzinga · 3d ago
Canaccord Genuity analyst Kyle Mikson maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $100 to $125.